Ovarian Cancer Survival in Missouri, 1996-2014

Overview

Journal Mo Med

Specialty General Medicine

Date 2019 Jan 16

PMID 30643350

Citations 1

Authors

Yilin Yoshida

Chester L Schmaltz

Jeanette Jackson-Thompson

Eduardo J Simoes

Affiliations

Soon will be listed here.

Abstract

We evaluated relative survival (RS) for ovarian cancer (OC) overall, by demographic and by clinicopathological characteristics in Missouri. Survival data from the Missouri Cancer Registry were obtained for cases diagnosed 1996-2014. An improved OC survival, especially in late stage, was observed in the study period. Our findings showed demographic, especially race-associated, and geographical variations of OC survival. OC survival also differed by first course treatment received and histology. These differences indicate disparities in OC care.

Citing Articles

GLUT5 increases fructose utilization in ovarian cancer.

Jin C, Gong X, Shang Y Onco Targets Ther. 2019; 12:5425-5436.

PMID: 31371983 PMC: 6635899. DOI: 10.2147/OTT.S205522.

References

Edwards B, Howe H, Ries L, Thun M, Rosenberg H, Yancik R . Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer. 2002; 94(10):2766-92. DOI: 10.1002/cncr.10593. View

Kaku T, Ogawa S, Kawano Y, Ohishi Y, Kobayashi H, Hirakawa T . Histological classification of ovarian cancer. Med Electron Microsc. 2003; 36(1):9-17. DOI: 10.1007/s007950300002. View

Murthy V, Krumholz H, Gross C . Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004; 291(22):2720-6. DOI: 10.1001/jama.291.22.2720. View

Talarico L, Chen G, Pazdur R . Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004; 22(22):4626-31. DOI: 10.1200/JCO.2004.02.175. View

Gansler T, Henley S, Stein K, Nehl E, Smigal C, Slaughter E . Sociodemographic determinants of cancer treatment health literacy. Cancer. 2005; 104(3):653-60. DOI: 10.1002/cncr.21194. View

Dohan D, Schrag D . Using navigators to improve care of underserved patients: current practices and approaches. Cancer. 2005; 104(4):848-55. DOI: 10.1002/cncr.21214. View

Lathan C, Neville B, Earle C . The effect of race on invasive staging and surgery in non-small-cell lung cancer. J Clin Oncol. 2005; 24(3):413-8. DOI: 10.1200/JCO.2005.02.1758. View

Hurria A, Fleming M, Baker S, Kelly W, Cutchall K, Panageas K . Pharmacokinetics and toxicity of weekly docetaxel in older patients. Clin Cancer Res. 2006; 12(20 Pt 1):6100-5. DOI: 10.1158/1078-0432.CCR-06-0200. View

Muss H, Berry D, Cirrincione C, Budman D, Henderson I, Citron M . Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol. 2007; 25(24):3699-704. DOI: 10.1200/JCO.2007.10.9710. View

10.

Huang L, Cronin K, Johnson K, Mariotto A, Feuer E . Improved survival time: what can survival cure models tell us about population-based survival improvements in late-stage colorectal, ovarian, and testicular cancer?. Cancer. 2008; 112(10):2289-300. DOI: 10.1002/cncr.23425. View

11.

Ji J, Forsti A, Sundquist J, Lenner P, Hemminki K . Survival in ovarian cancer patients by histology and family history. Acta Oncol. 2008; 47(6):1133-9. DOI: 10.1080/02841860701784544. View

12.

Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A . Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009; 10(4):327-40. DOI: 10.1016/S1470-2045(09)70026-9. View

13.

Henry K, Niu X, Boscoe F . Geographic disparities in colorectal cancer survival. Int J Health Geogr. 2009; 8:48. PMC: 2724436. DOI: 10.1186/1476-072X-8-48. View

14.

Shayne M, Culakova E, Wolff D, Poniewierski M, Dale D, Crawford J . Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy. Cancer. 2009; 115(22):5319-28. DOI: 10.1002/cncr.24560. View

15.

Morris C, Sands M, Smith L . Ovarian cancer: predictors of early-stage diagnosis. Cancer Causes Control. 2010; 21(8):1203-11. DOI: 10.1007/s10552-010-9547-0. View

16.

Foster J, Salinas G, Mansell D, Williamson J, Casebeer L . How does older age influence oncologists' cancer management?. Oncologist. 2010; 15(6):584-92. PMC: 3227998. DOI: 10.1634/theoncologist.2009-0198. View

17.

Vergote I, Trope C, Amant F, Kristensen G, Ehlen T, Johnson N . Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010; 363(10):943-53. DOI: 10.1056/NEJMoa0908806. View

18.

Lee L, Cheung W, Atkinson E, Krzyzanowska M . Impact of comorbidity on chemotherapy use and outcomes in solid tumors: a systematic review. J Clin Oncol. 2010; 29(1):106-17. DOI: 10.1200/JCO.2010.31.3049. View

19.

Buys S, Partridge E, Black A, Johnson C, Lamerato L, Isaacs C . Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011; 305(22):2295-303. DOI: 10.1001/jama.2011.766. View

20.

Caillet P, Canoui-Poitrine F, Vouriot J, Berle M, Reinald N, Krypciak S . Comprehensive geriatric assessment in the decision-making process in elderly patients with cancer: ELCAPA study. J Clin Oncol. 2011; 29(27):3636-42. DOI: 10.1200/JCO.2010.31.0664. View